• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TRABECTEDIN Drug Record

  • Summary
  • Interactions
  • Claims
  • TRABECTEDIN chembl:CHEMBL450449 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    ECTEINASCIDINS TRABECTEDIN
    TRABECTEDIN
    YONDELIS
    NSC-648766
    ET-743
    ECTEINASCIDIN 743
    ET743
    ECT 743
    YONDELIS®
    ECTEINASCIDIN
    chemidplus:114899-77-3
    pubchem.compound:108150
    drugbank:05109
    chembl:CHEMBL450449
    rxcui:1716278

    Drug Info:

    (0 More Sources)

    Publications:

    Künstlinger et al., 2015, FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro., Oncotarget
    Laurenty AP et al., 2013, Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case report., Pharmacogenomics
    Pignochino Y et al., 2017, PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models., Mol Cancer
  • TRABECTEDIN   PARP1

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28454547


    Sources:
    CIViC

  • TRABECTEDIN   FGFR2

    Interaction Score: 0.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Dovitinib + Trabectedin
    Indication/Tumor Type myxoid liposarcoma
    Response Type sensitive

    PMIDs:
    26036639


    Sources:
    JAX-CKB

  • TRABECTEDIN   ABCB1

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24024892


    Sources:
    PharmGKB

  • JAX-CKB: Trabectedin

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Künstlinger et al., 2015, FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro., Oncotarget

  • PharmGKB: trabectedin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Laurenty AP et al., 2013, Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case report., Pharmacogenomics

  • CIViC: TRABECTEDIN

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Pignochino Y et al., 2017, PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models., Mol Cancer

  • ChemblDrugs: chembl:CHEMBL450449

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21